Kasner S E, Lynn M J, Chimowitz M I, Frankel M R, Howlett-Smith H, Hertzberg V S, Chaturvedi S, Levine S R, Stern B J, Benesch C G, Jovin T G, Sila C A, Romano J G
Department of Neurology, University of Pennsylvania Medical Center, Philadelphia, PA, USA.
Neurology. 2006 Oct 10;67(7):1275-8. doi: 10.1212/01.wnl.0000238506.76873.2f.
The WASID trial showed no advantage of warfarin over aspirin for preventing the primary endpoint of ischemic stroke, brain hemorrhage, or vascular death. In analyses of selected subgroups, there was no definite benefit from warfarin. Warfarin reduced the risk of the primary endpoint among patients with basilar artery stenosis, but there was no reduction in stroke in the basilar artery territory or benefit for vertebral artery stenosis or posterior circulation disease in general.
华法林-阿司匹林症状性颅内疾病试验（WASID）表明，在预防缺血性卒中、脑出血或血管性死亡等主要终点方面，华法林并不比阿司匹林更具优势。在对选定亚组的分析中，华法林也没有明确的益处。华法林降低了基底动脉狭窄患者发生主要终点事件的风险，但在基底动脉供血区域的卒中发生率并没有降低，总体上对椎动脉狭窄或后循环疾病也没有益处。
